RT Journal Article
SR Electronic
T1 A randomized open-label, observational study of the novel ketone ester, bis octanoyl (R)-1,3-butanediol, and its acute effect on ß-hydroxybutyrate and glucose concentrations in healthy older adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.16.24305925
DO 10.1101/2024.04.16.24305925
A1 Stephens, Elizabeth B.
A1 Senadheera, Chatura
A1 Roa-Diaz, Stephanie
A1 Peralta, Sawyer
A1 Alexander, Laura
A1 Silverman-Martin, Wendie
A1 Yukawa, Michi
A1 Morris, Jenifer
A1 Johnson, James B.
A1 Newman, John C.
A1 Stubbs, Brianna J.
YR 2024
UL http://medrxiv.org/content/early/2024/04/18/2024.04.16.24305925.abstract
AB Bis-octanoyl (R)-1,3-butanediol (BO-BD) is a novel ketone ester (KE) ingredient which increases blood beta-hydroxybutyrate (BHB) concentrations rapidly after ingestion. KE is hypothesized to have beneficial metabolic effects on health and performance, especially in older adults. Whilst many studies have investigated the ketogenic effect of KE in young adults, they have not been studied in an exclusively older adult population, for whom age-related differences in body composition and metabolism may alter the effects. This randomized, observational, open-label study in healthy older adults (n = 30, 50% male, age = 76.5 years, BMI = 25.2 kg/m2) aimed to elucidate acute tolerance, blood BHB and blood glucose concentrations for 4 hours following consumption of either 12.5 or 25 g of BO-BD formulated firstly as a ready-to-drink beverage (n = 30), then as a re-constituted powder (n = 21), taken with a standard meal. Both serving sizes and formulations of BO-BD were well tolerated, and increased blood BHB, inducing nutritional ketosis (≥ 0.5mM) that lasted until the end of the study. Ketosis was dose responsive; peak BHB concentration (Cmax) and incremental area under the curve (iAUC) were significantly greater with 25 g compared to 12.5 g of BO-BD in both formulations. There were no significant differences in Cmax or iAUC between formulations. Blood glucose increased in all conditions following the meal; there were no consistent significant differences in glucose response between conditions. These results demonstrate that both powder and beverage formulations of the novel KE, BO-BD, induce ketosis in healthy older adults, facilitating future research on functional effects of this ingredient in aging.Competing Interest StatementB.J.S. has stock in H.V.M.N Inc, and stock options in Selah Therapeutics Ltd, BHB Therapeutics (Ireland) Ltd., and Juvenescence Ltd. J.C.N. has stock options in Selah Therapeutics Ltd and BHB Therapeutics (Ireland) Ltd. J.C.N and B.J.S. are inventors on patents related to the use of ketone bodies. B.J.S and J.C.N have disclosed those interests fully to The Buck Institute, and have in place an approved plan for managing any potential conflicts arising from this arrangement. All other authors have no competing interestsClinical TrialNCT05585762Clinical Protocols https://www.medrxiv.org/content/10.1101/2023.10.25.23297571v1 Funding StatementThis work was funded by a philanthropic donation to the Buck Institute by The Buck Institute Impact Circle and by Dr James B. Johnson. Dr Johnson provided input into study design but had no role in study conduct, data analysis or interpretation. The study beverages were provided by BHB Therapeutics (Ireland) Limited, which is licensed to develop products related to ketone bodies. BHB Therapeutics had no role in the design, conduct, analysis, or interpretation of the study. J.C.Ns participation was supported by Buck Institute institutional funds. B.J.Ss participation was supported by the National Institute on Aging K01AG078125.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Addvara IRB gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data presented here may be available upon reasonable request from the corresponding author and in accordance with intellectual property considerations.